Skip to main content

Alzheimer’s Drugs Market Size [2022-2028] | Industry Size, Share, Growth, Trends & Forecast Analysis

Written by Customer Service on . Posted in Mergers And Acquisitions.

Key Prominent Players Covered in the Alzheimer’s Drugs Market Research Report Are Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Eli Lilly and Company., Merck Sharp & Dohme Corp., AstraZeneca, Biogen, AbbVie Inc., ALLERGAN, other players

Pune, India, May 05, 2022 (GLOBE NEWSWIRE) — Increasing prevalence of Alzheimer’s disease is fueling the demand for Alzheimer’s drugs which in turn is driving the global Alzheimer’s drugs market, says Fortune Business Insights in a report, titled Alzheimer’s Drugs Market Size , Share and Global Trend By Drug Class (Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Antagonist, Combination Drugs, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography Forecast till 2026.

Rising R&D activities by pharmaceutical companies and research institutes for Alzheimer effective therapy is expected to boost the global Alzheimer’s drugs market.

Request a Sample Copy of the Research Report:

https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/alzheimers-drugs-market-101033


Alzheimer’s Drugs Industry Developments    

  • In April 2019, the Alzheimer’s Drug Discovery Foundation (ADDF), announced a new initiative -Diagnostics Accelerator program that aims to track the development of digital tools for Alzheimer’s disease and dementia.
  • In December 2018, Eli Lilly and Company and AC Immune collaborated to develop new treatment for Alzheimer’s disease using AC Immune’s Morphomer platform.

Key Research Objectives

  • Market size and growth rate by various segments at global and regional level for the 2015-2026 period, with 2015-2017 as historical data, 2018 as base year and 2019-2026 as forecast period
  • Overall market size and growth rate for key countries for the 2015-2026 period
  • Market dynamics – Market drivers, restraints, trends and opportunities
  • Technological and market developments shaping the market
  • Competitive analysis
  • Profiles of key companies operating in the market
  • Key insights

Increasing R&D Investments by Pharmaceutical Companies Will Propel Growth 

The active study of Alzheimer’s drug by pharmaceutical industries and research institutes for creating a strong pipeline for effective therapy is predicted to encourage growth of the global Alzheimer’s drugs market. According to the World Health Organization (WHO) currently, 50 million people are affected by dementia, and the number is expected to increase during the forecast period. In addition, the increasing cases of Alzheimer’s disease around the world have led towards high demand for Alzheimer’s drugs, which in turn is boosting the global Alzheimer’s drugs growth. However, discontinuation of clinical trials for Alzheimer’s drugs by leading pharmaceutical companies which is resulting in limited treatment options and thus creating a global economic burden by increasing the nation’s annual treatment cost against Alzheimer’s drugs development and disease treatment. This factor is predicted to hamper the growth of the global Alzheimer’s drugs market during the forecast period. For instance, Eisai and Biogen, Co., Ltd., declared the termination of phase 3 clinical trial of ENGAGE and EMERGE designed to evaluate the safety and efficacy in the treatment of Alzheimer’s disease.

The Collaboration Between Eli Lilly and AC Immune Will Aid Growth 

Eli Lilly and Company and AC Immune SA announced their partnership agreement to research and develop tau aggregation inhibitor small molecules for the potential treatment of Alzheimer’s disease (AD) and other neurodegenerative diseases. The collaboration between the two companies is predicted to benefit Alzheimer’s drugs revenue owing to the Morphomer™ platform technology which will offer commercial capabilities in central nervous system disorders along with AC Immune’s lead molecule, ACI-3024. Furthermore, the development of digital tools for Alzheimer’s disease and dementia is also expected to contribute to the global Alzheimer’s drugs growth. For instance, the Alzheimer’s Drug Discovery Foundation (ADDF), announced a new initiative -Diagnostics Accelerator program that aims to track the development of digital tools for Alzheimer’s disease and dementia.

For more information in the analysis of this report, visit:

https://www.fortunebusinessinsights.com/industry-reports/alzheimers-drugs-market-101033


Regional Analysis:

The global Alzheimer’s drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The global Alzheimer’s drugs market is anticipated to expand in North America during the forecast period owing to growing prevalence of Alzheimer’s disease and presence of global players. According to Alzheimer’s Association, currently, 5.8 million Americans are living with Alzheimer’s, and the number is expected to increase to 14 million by 2050, which is expected to drive the Alzheimer’s drugs market in North America. In Europe, the increasing cases of Alzheimer’s disease, coupled with improving diagnostic capabilities, are projected to augment the market by the end of 2026. In Asia Pacific and Latin America, evolving healthcare infrastructure and raising awareness regarding Alzheimer’s disease are anticipated to fuel the Alzheimer’s drugs market growth during the forecast period. Additionally, Alzheimer’s drugs market in Middle East & Africa is in nascent stage; however, unmet needs for Alzheimer’s disease is expected to drive the Alzheimer’s drugs market in this region.

Leading Players operating in the Alzheimer’s Drugs Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

  • Hoffmann-La Roche Ltd,
  • Novartis AG,
  • Pfizer Inc.,
  • Eli Lilly and Company.,
  • Merck Sharp & Dohme Corp.,
  • AstraZeneca,
  • Biogen,
  • AbbVie Inc.,
  • ALLERGAN,
  • other players

Have Any Query? Ask Our Experts:

https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/alzheimers-drugs-market-101033

Increasing Prevalence of Alzheimer’s Disease Will Boost Growth in North America

Geographically, the global Alzheimer’s drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The global Alzheimer’s drugs market is predicted to expand in North America during the forecast period owing to the rising cases of Alzheimer’s disease and the presence of key players in the region. According to Alzheimer’s Association, currently, 5.8 million Americans are living with Alzheimer’s, and the number is expected to increase to 14 million by 2050, which is expected to promote the growth of the Alzheimer’s drugs market in North America. Europe is predicted to grow significantly during the forecast period owing to the increasing prevalence of Alzheimer’s disease. Improving diagnostic capabilities are also expected to boost the market in the region. Evolving healthcare infrastructure and rising awareness regarding Alzheimer’s disease are expected to contribute significantly to Alzheimer’s drugs growth in Asia Pacific and Latin America. Additionally, Alzheimer’s drugs market in Middle East & Africa is in the nascent stage; however, unmet needs for Alzheimer’s disease is expected to drive the Alzheimer’s drugs market in this region.

Global Alzheimer’s Drugs Market Segmentation

By Drug Class 

  • Cholinesterase Inhibitors
  • N-Methyl-D-Aspartate (NMDA) Antagonist
  • Combination Drugs
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Application

  • North America (USA and Canada)
  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/alzheimers-drugs-market-101033


About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.